Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEZURSO 2: Bezafibrate in PBC with Non-optimal Response to UDCA
NCT06443606Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bezafibrate in primary biliary cholangitis (PBC) (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Proportion of patients with a complete biochemical response at 48 weeks. Started Mar 2025; status: recruiting.
02
Drugs
bezafibrate
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT06443606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06443606.